ASML, Vistra, and Hesai Are On Sale
The artificial intelligence boom is alive and well. That makes the dip after ASML's posting quarterly results unusual.ASML lost 8.33% on Wednesday after posting results that beat estimates. Revenue grew by 23% Y/Y to EUR 7.69 billion. In Q3, the lithography machine supplier is forecasting net sales of between EUR 7.4 billion and EUR 7.9 billion.Investors feared that ASML’s prospects for 2026 are uncertain. The CFO, Roger Dassen, said that tariffs are a threat to business conditions. He said that tariffs could have an impact on shipments to the U.S., on imported parts and tools, on required material imports, and tariffs applied from other countries on U.S. exports.Consider taking advantage of ASML stock at sale prices this morning.Vistra (VST) potentially peaked at around $200. The stock continued to pull back, closing at $184.13. The EPA is lowering greenhouse gas emission limitations from power plants. This is long-term beneficial for Vistra’s energy production growth.Hesai (HSAI) dropped by 9.29% on Wednesday in the absence of any news. In Q1, posted on May 27, the firm reported revenue of $72.4 million (+46.3% Y/Y). It shipped 146,087 ADAS lidar units, nearly double the year before. In Q2, its expected revenue of up to $99.2 million represents growth of up to 57%.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


